Drugs / [225Ac]Ac-DOTATATE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07413042 | Jan → Dec 2026 expected | small cell lung carcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06732505 | Sep 2024 → Dec 2025 overdue | neuroendocrine neoplasm | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [225Ac]Ac-DOTATATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06732505 ↗ |
| Modality | Other / unclassified | “Investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine neoplasms” NCT06732505 ↗ |